(Its sibling product, Wegovy, contains the same semaglutide but is approved specifically for chronic weight management.) That appetite-taming, stomach-slowing action is exactly why semaglutide is so effective and also why it produces gastrointestinal side effects in some people
Tirzepatide, as a dual GIP/GLP-1 receptor agonist, works through an additional pathway by also activating glucose-dependent insulinotropic polypeptide (GIP) receptors, which may influence its gastrointestinal tolerability profile compared to pure GLP-1 agonists
Patients with certain genetic profiles may be predisposed to stronger initial side effects or faster adaptation
This creates a record that becomes valuable because you consistently add to it
For example, conditions such as thyroid disorders , polycystic ovary syndrome (PCOS) , and insulin resistance can affect how well these medications manage appetite and metabolism